Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL360054 | 0.99 | KMT2A (0.36) | KMT2AMEN1TAAR1LIPECYP2D6 | |
| SCHEMBL359943 | 0.89 | KMT2A (0.39) | KMT2AMEN1TAAR1LIPEALDH1A1 | |
| SCHEMBL360882 | 0.88 | MEN1 (0.41) | KMT2AMEN1LIPECYP2D6ALDH1A1 | |
| SCHEMBL15344567 | 0.76 | — | — | |
| SCHEMBL15344566 | 0.76 | CNR1 (0.34) | ALDH1A1PLA2G1BNPSR1ATG4BCNR1 | |
| SCHEMBL360687 | 0.76 | KMT2A (0.32) | KMT2AMEN1ALDH1A1PLA2G1BNPSR1 | |
| SCHEMBL15344560 | 0.75 | KMT2A (0.31) | KMT2ACNR1CNR2 | |
| SCHEMBL15344559 | 0.75 | CNR1 (0.36) | LIPEALDH1A1PLA2G1BNPSR1ATG4B | |
| SCHEMBL360055 | 0.75 | KMT2A (0.34) | KMT2AMEN1ALDH1A1PLA2G1BNPSR1 | |
| SCHEMBL360469 | 0.73 | KMT2A (0.37) | KMT2AMEN1CYP2D6ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312688-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-26 | — | — | US | disclosed |
| US-20200308119-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2020-10-01 | — | — | US | disclosed |
| US-10723703-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-07-28 | — | — | US | disclosed |
| US-20190084938-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2019-03-21 | — | — | US | disclosed |
| US-10183913-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-01-22 | — | — | US | disclosed |
| US-10087146-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-10-02 | — | — | US | disclosed |
| US-20180273489-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2018-09-27 | — | — | US | disclosed |
| US-20170217902-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2017-08-03 | — | — | US | disclosed |
| US-9663472-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| EP-2594559-B1 | PYRAZOLE COMPOUND | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20140315971-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2014-10-23 | — | — | US | disclosed |
| US-20140031406-A1 | PYRAZOLE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| EP-2594559-A1 | PYRAZOLE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116296-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2013-05-09 | — | — | US | disclosed |
| WO-2012008528-A1 | PYRAZOLE COMPOUND | 大日本住友製薬株式会社 (JP) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315971-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885MEN1 3975/4885TAAR1 73/4885 |
| US-10183913-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885MEN1 3975/4885TAAR1 73/4885 |
| US-20170217902-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885MEN1 3975/4885TAAR1 73/4885 |
| US-11312688-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885MEN1 3975/4885TAAR1 73/4885 |
| US-20130116296-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885MEN1 3975/4885TAAR1 73/4885 |
| US-20200308119-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885MEN1 3975/4885TAAR1 73/4885 |
| US-10723703-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885MEN1 3975/4885TAAR1 73/4885 |
| US-20180273489-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885MEN1 3975/4885TAAR1 73/4885 |
| US-20190084938-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885MEN1 3975/4885TAAR1 73/4885 |
| US-10087146-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885MEN1 3975/4885TAAR1 73/4885 |
| US-20140031406-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885MEN1 3975/4885TAAR1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.